When the mice with complete response (CR) in the Met@Man-MPs and anti-PD-1 antibody-treated group were again inoculated with H22 cells at 70 d after initial treatment, 100% of the mice rejected the tumor rechallenge up to 25 d, while continuous tumor growth was observed in naïve mice inoculated in parallel with the same number of cells (Fig. 8k). This evidence concerns the gene PDCD1 and neoplasm.